Because of the greater resistance of Streptococcus faecalis and Streptococcus faecium to antimicrobial agents as compared with the resistance of other streptococci, rapid identification and knowledge of susceptibility patterns of these two species are important in the institution of appropriate early treatment of infection. Several methods which have been described for identification of these organisms make take from 4 to 48 h (2, 7). This study evaluated Strep Trio-Tubes S4, S5, and S3 for identification of S. faecalis and S. faecium and compared them with conventional methods for accuracy and time to identification. The in vitro activities of current antimicrobial agents, i.e., ampicillin, erythromycin, and vancomycin, commonly used in the treatment of enterococcal infections were determined by MIC microdilution susceptibility studies. In addition to these drugs, MIC testing was performed with several newer antimicrobial agents, including imipenem (a broad-spectrum carbapenem drug), and seven new quinolone drugs: CI-934, enoxacin, ciprofloxacin, amifloxacin, norfloxacin, A-56619, and A-56620. Imipenem and the quinolones have been shown to have various degrees of activity against enterococci (1, 3, 5, 6, 8, 10, 11) . MBCs were determined with CI-934, the quinolone which exhibited the greatest degree of activity against the enterococcal isolates.
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MATERIALS AND METHODS
Bacterial strains. A total of 301 enterococcal isolates from blood and urine samples were collected at Evanston Hospital, Evanston, Ill., over a period of 5 months. All isolates were subcultured on sheep blood agar plates and incubated * Corresponding author.
in 5% C02 at 35°C for 24 h before identification and susceptibility studies.
Identification. Identification of S. faecalis and S. faecium was determined with Strep Trio-Tubes S4, S5, and S3, and conventional methods based on the Facklam scheme for differentiation of group D streptococci (7). Gram-positive cocci, morphologically consistent with enterococci, were inoculated into conventional media consisting of bile esculin agar, 6 .5% NaCl agar, arginine decarboxylase, and mannitol, as weil as arabinose and sorbitol heart infusion broths (Remel, Lenexa, Kans.). Those isolates which were (i) NaCl tolerant, (ii) positive in bile esculin agar, arginine, mannitol, and sorbitol, and (iii) negative in arabinose were identified as S. faecalis. Isolates which were (i) NaCl durans is commonly isolated from milk and dairy products and is rarely isolated from specimens of human origin.
Further biochemical testing would be appropriate in laboratories that commonly isolate S. durans strains.
Although additional carbohydrates were used, five nonhemolytic isolates remained unidentified by either system. All five isolates exhibited similar biochemical reactions. Esculin, PYR, arginine, hippurate, pyruvate, mannitol, and lactose were positive with Trio-Tubes; there were negative reactions in starbose, sorbitol, raffinose, and inulin. Bile esculin agar, NaCI, arginine, mannitol, sucrose, and lactose were positive by conventional methods, and arabinose, sorbitol, raffinose, and inulin remained negative. According to the percentage tables included with the Trio-Tube identification system, 98% of S. faecalis isolates are pyruvate and sorbitol positive. Our isolates were sorbitol negative. S. faecium is pyruvate and sorbitol negative. Pyruvate was not tested in our conventional scheme. The need for further identification methods to elucidate the species of these five enterococcal isolates points out that the Trio-Tubés are somewhat limited, as was the conventional methods used, in their ability to distinguish all enterococcal strains. Strep Trio-Tubes are recommended for the presumptive identification of groups A, B, and D and viridans group streptococci; thus further testing with certain aberrant strains can be anticipated.
The results of the microdilution susceptibility studies can be seen in Table 1 . A total of 260 S. faecalis and 12 S.
faecium isolates were tested. Ampicillin and vancomycin exhibited the greatest activity against S. faecalis, with an ampicillin MIC90 of 1 ,ug/ml and a vancomycin MIC9 of 2 ,ug/mI. Erythromycin exhibited a MIC90 of >16 itg/ml for S.
faecalis. For S. faecium, the MIC90s were 2 ,ug of vancomycin per ml, 16 jxg of ampicillin per ml, and >16 ,ug of erythromycin per ml. CI-934, the most active quinolone tested, showed MIC90s for S.faecalis and S.faecium strains at concentrations of 0.5 and 1 ,ug/mI, respectively. The MICgo of ciprofloxacin for S. faecalis strains was 2 ,ug/mI. For S. faecalis strains, the order of MICgos among the other quinolone antimicrobial agents was 4,ug/ml (norfloxacin and A-56620) > 8 p.g/ml (A-56619 and enoxacin) > 16 pg/ml (amifloxacin).
With S. faecium, ciprofloxacin showed a MIC90 of 4 ,ug/ml, norfloxacin exhibited 8,ug/ml, A-56619 and A-56620 showed 16,ug/ml, and amifloxacin exhibited >16,ug/ml. Imipenem had a MIC50 for the S. faecalis isolates of 1 ,ug/ml and a MIC90 of 2,ug/ml; however, imipenem was much less active against S. faecium, with a MIC90 of >16,ug/ml. CI-934, the only antimicrobial agent tested for MBC activity, exhibited MBC90s of 1 and 2,ug/ml, respectively, against S. faecalis and S. faecium strains.
DISCUSSION
Rapid identification to species level and susceptibility testing of enterococci in the clinical laboratory is not routinely necessary; however, in some instances, it could aid the physician in the choice of appropriate antimicrobial therapy. The Trio-Tubes provide a system for species identification of enterococcal isolates which is accurate, rapid, and more cost effective than the conventional methods used. The cost of each Trio-Tube is one-third the cost of each carbohydrate heart infusion broth. For most isolates, identification of S. faecalis and preliminary identification of S. faecium can be obtained in 4 h. With S. faecium, a more resistant species, rapid identification of this organism could be very important in the management of patient therapy (4), especially when this organism is isolated from a significant blood culture. Species identification of enterococci has also been found to be of epidemiological importance and has been used to establish awareness of nosocomial outbreaks (4).
The MICgos of ampicillin (1 ,ug/mi), vancomycin (2 ,ug/mi), and erythromycin (>16 ,utg/ml) against S. faecalis are similar to those reported in the literature (1, 11, 17) . The MIC90 obtained for ampicillin (16 ,tg/ml) with respect to S. faecium demonstrates that it is a more resistant organism.
A number of MIC in vitro studies have been published showing the quinolones, which are derivatives of nalidixic acid, to have a broad range of activity against bacteria, including gram-positive as well as gram-negative organisms (5, 6, 8, 10 For all but two of the quinolones tested, CI-934 and ciprofloxacin, the MICgos for the S. faecalis strains tested were greater than or equal to 4 ,ug/ml. Because of high obtainable levels of the drugs in urine samples and the broad activity gainst gram-negative bacilli, many of the quinolones could be used as single antimicrobial agents in the treatment of mixed urinary tract infections; however, the activity against enterococci is not great enough to use alone in the treatment of severe systemic infections, e.g., bacterial endocarditis (6, 10) . Perhaps the quinolones will be advantageous in treating urinary tract infections because of their activity against enterococci and staphylococci, two groups which commonly occur as superinfecting organisms (8) . . Because of their activity against the enterococci, the quinolones may be useful in preventing nosocomial infections due to these organisms.
Of the 11 antimicrobial agents tested against S. faecalis strains, the most potent was CI-934, a quinolone specifically developed for increased activity against gram-positive cocci (3). It also exhibited good activity against S. faecium, although only 12 strains were tested. CI-934, when tested for MBCs against enterococcal isolates, exhibited good bactericidal activity, with MICgos of 1 utg/mI or less for S. faecalis and 2 ,ug/ml or less for S. faecium strains. It appears that this antimicrobial agent may have great potential for use with urinary and systemic infections, but further clinical studies are indicated.
Imipenem, an agent known to have a very broad antimicrobial spectrum, inhibited 90% of the S. faecalis urine and blood isolates at 2 ,ugIml. This datum is consistent with several studies performed with imipenem against enterococci isolates from urine specimens, as well as isolates from pelvic, intra-abdominal, and soft tissue infections (1, 9, 11, 12, 15) . Imipenem shows a promising advantage for use in therapy against enterococcal infections, because it exhibits good activity against these organisms, whereas other betalactam antibiotics do not, and can probably be used alone or in combination with gentamicin to increase its bactericidal activity (1, 13) .
